About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« A Good Example of Phenotypic Screening | Main | Your Press Release Has Already Been Written »

November 16, 2012

Hexacyclinol Round-Up

Email This Entry

Posted by Derek

For those wanting a timeline of the whole hexacyclinol business, with links to the articles, blogs, and commentary that's surrounded it, allow me to recommend Carmen Drahl's "History of the Hexacyclinol Hoo-Hah". (And no, the whole thing is not written in alliteration; for that, you'll be wanting this).

Comments (4) + TrackBacks (0) | Category: Chemical News | The Scientific Literature


1. Anonymous on November 16, 2012 9:57 AM writes...

Books written about a route to a molecule which nobody would actually time and money spent by others what is the actual harm for the chemical community??? Actually, if one thinks a little bit more, JJ Le Clair's paper have help a lot to highlight how imperfect and susceptible of irregularities the peer-review and editorial system

Then, some big respected academic reports some methodology with many, let's called "dark aspects and inaccuracies" which actually would constitute a real advance to be used on the daily basis by many chemist in the academic and industrial stage, and absolutely nobody says anything about the time and money harm caused.

Hypocrisy and science..."The marriage plot"

Permalink to Comment

2. Cato the Elder on November 16, 2012 2:19 PM writes...

Actually props to JJ... he just pulled the biggest troll in the history of organic chemistry

Permalink to Comment

3. Stephen on November 17, 2012 8:21 AM writes...

Have you seen JJ? He *looks* like the biggest troll in the history of organic chemistry.

Permalink to Comment

4. Aubry K. Miller on November 14, 2014 5:10 AM writes...

I gave the talk at the 2006 Fall ACS meeting right before La Clair (guanacastepene E TS). Made me feel really happy and important that so many people were there to hear my talk. I realized afterwards, of course, that they weren't there for me at all. So it goes. :)

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry